HAYWARD,
Calif., April 27, 2023 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for use in medically
supervised settings, today announced that it will release first
quarter financial results for 2023 after the market close
on Wednesday, May 10, 2023. Thereafter, AcelRx management will
host a live webcast and conference call at 4:30 p.m. Eastern
Daylight Time/1:30 p.m. Pacific Daylight
Time on May 10, 2023 to discuss the financial
results and provide an update on the Company's business.
Webcast Information
The webcast can be accessed here
or by visiting the "Investors" section of the Company's website
at www.acelrx.com and clicking on the webcast link within
the News & Events/Upcoming Events section. The webcast will
include a slide presentation and a replay will be available on the
AcelRx website for 90 days following the event.
Conference Call Information
Investors who wish to
participate in the conference call may do so by dialing
1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian
callers, 1-412-902-4204 (toll applies) for international callers.
The conference ID is 10177890.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's lead product
candidate, Niyad is a lyophilized formulation of nafamostat and is
currently being studied under an investigational device exemption,
or IDE, as an anticoagulant for the extracorporeal circuit, and has
received Breakthrough Device Designation Status from the FDA.
AcelRx is also developing two pre-filled syringes in-licensed from
its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe,
with an expected NDA filing in the first half of 2023, and PFS-02,
a pre-filled phenylephrine syringe with an expected NDA filing in
2024.
This release is intended for investors only. For
additional information about AcelRx, please
visit www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-first-quarter-2023-financial-results-call-and-webcast-on-may-10-2023-301810122.html
SOURCE AcelRx Pharmaceuticals, Inc.